Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study

Afatinib, an irreversible ErbB-family blocker, could improve the survival of advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients (NSCLCm+). This phase II trial (NCT04201756) aimed to assess the feasibility of neoadjuvant Afatinib treatment for stage III NSCLCm...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Dongliang, Sun, Liangdong, Hu, Junjie, Duan, Liang, Xia, Haoran, Zhu, Xinsheng, Sun, Fenghuan, Zhang, Lele, Yu, Huansha, Xiong, Yicheng, Huang, Zhida, Zhao, Deping, Song, Nan, Yang, Jie, Bao, Xiao, Wu, Wei, Huang, Jie, He, Wenxin, Zhu, Yuming, Jiang, Gening, Zhang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400609/
https://www.ncbi.nlm.nih.gov/pubmed/37537219
http://dx.doi.org/10.1038/s41467-023-40349-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400609/
https://www.ncbi.nlm.nih.gov/pubmed/37537219
http://dx.doi.org/10.1038/s41467-023-40349-z

Ejemplares similares